DHEA (Dehydroepiandrosterone)

DHEA (Dehydroepiandrosterone) is the most abundant circulating steroid hormone precursor in the human body, produced primarily by the adrenal glands. DHEA levels peak in early adulthood and decline significantly with age. It is foundational in HRT and anti-aging protocols for both men and women, serving as a precursor to both androgens and estrogens.

Category
Hormonal Support
Demand
High
Route
Oral capsule, topical cream, sublingual, vaginal insert
FDA status
Available as supplement (OTC) and compounded prescription. FDA-approved topical (Intrarosa) for vaginal atrophy. Compounding eligibility varies by formulation
Also known as
DehydroepiandrosteroneDHEA-S

How DHEA (Dehydroepiandrosterone) Works

DHEA is synthesized from pregnenolone via CYP17A1 in the adrenal zona reticularis [4]. It serves as a precursor to both androgens (via conversion to androstenedione and testosterone) and estrogens (via aromatase) [1]. DHEA also has direct receptor interactions, including sigma-1 receptor agonism (neuroprotective), PPAR-alpha activation (anti-inflammatory), and modulation of IGF-1 signaling [4]. Its sulfated form (DHEA-S) serves as a circulating reservoir with a longer half-life.

Clinical Evidence

Large epidemiological studies confirm age-related DHEA decline correlates with increased cardiovascular risk, bone loss, and cognitive decline [4]. The DHEAge study (Baulieu et al., 2000) showed improvements in bone density, skin, and libido in women over 70 receiving 50mg daily [1]. For vaginal atrophy, prasterone (DHEA vaginal insert) received FDA approval based on strong Phase III data demonstrating significant improvement in moderate-to-severe dyspareunia [2].

Clinical Uses

  • Hormone replacement foundation in HRT protocols (androgen and estrogen precursor)
  • Adrenal support and adrenal insufficiency management
  • Bone density maintenance and osteoporosis prevention
  • Immune function support and inflammatory modulation
  • Vaginal atrophy treatment (topical, FDA-approved as Intrarosa)

Patient Selection and Screening

Candidates include patients with documented low DHEA-S for age, adrenal insufficiency [3], or those on full HRT protocols requiring androgen precursor support [4]. Gender-specific dosing is essential, as women are significantly more sensitive to androgenic effects [1]. Screen for hormone-sensitive cancers before initiating. Patients with PCOS or elevated androgens at baseline are generally not candidates.

Dosing and Administration

For men, initiate at 25-50mg oral daily and titrate to target DHEA-S levels appropriate for age (typically 300-500 mcg/dL for men aged 40-60) [4]. For women, start at 5-10mg daily and titrate cautiously, monitoring for androgenic side effects [3]. Recheck DHEA-S, testosterone, and estradiol at 6-8 weeks [1]. For vaginal atrophy, FDA-approved prasterone (Intrarosa) provides 6.5mg intravaginal daily with minimal systemic absorption [2].

Route
Oral capsule, topical cream, sublingual, vaginal insert
Protocol notes
Oral capsule (men: 25-100mg daily; women: 5-25mg daily). Gender-specific dosing is critical. Micronized formulations improve absorption. Topical cream available for local applications. Monitor DHEA-S levels to guide dosing.

Safety and Monitoring

Potential side effects

  • Acne and oily skin (androgenic conversion, more common in women)
  • Hirsutism and hair thinning in women at higher doses
  • Mood changes (irritability or aggressiveness if testosterone conversion is excessive)
  • Insomnia (particularly with evening dosing)
  • Potential HDL reduction with chronic high-dose use

Clinical considerations

  • Monitor DHEA-S levels and downstream androgens/estrogens regularly
  • May cause acne, oily skin, or hair changes (hirsutism in women) at higher doses due to androgenic conversion
  • Gender-specific dosing essential (women require significantly lower doses than men)
  • Contraindicated in hormone-sensitive cancers (converts to testosterone and estrogen)
  • Can affect lipid profiles; monitor HDL/LDL periodically

Practice Economics

DHEA is a high-volume, foundational compound in HRT practices with strong margins when compounded as pharmaceutical-grade formulations [4]. The differentiation between OTC supplements and clinical-grade compounded DHEA (precise dosing, micronized, specialized delivery forms) justifies prescription management fees [3]. It anchors full hormone panels and drives recurring lab monitoring revenue [1]. The FDA-approved Intrarosa pathway also provides a covered indication for appropriate female patients [2].

FDA Category Status

Available as supplement (OTC) and compounded prescription. FDA-approved topical (Intrarosa) for vaginal atrophy. Compounding eligibility varies by formulation

FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.

Frequently Asked Questions

Why prescribe compounded DHEA when it is available over the counter?

Compounded DHEA offers pharmaceutical-grade purity, precise dosing (especially important for low-dose female formulations like 5mg or 10mg), micronized formulations with better absorption, and specialized delivery forms (topical, sublingual, vaginal) not available OTC. Clinical DHEA protocols also include monitoring and dose adjustment that distinguish medical management from self-supplementation.

What are the key differences in DHEA dosing between men and women?

Women are much more sensitive to DHEA's androgenic effects due to lower baseline androgen levels. Typical female doses are 5-25mg daily, while men may use 25-100mg daily. Women should start at 5-10mg and titrate slowly while monitoring for androgenic side effects (acne, hair growth, voice changes). DHEA-S and free testosterone levels guide dose adjustment in both sexes.

How does DHEA fit into a full HRT protocol?

DHEA serves as a foundational precursor in HRT protocols, supporting both androgen and estrogen production. In men, it complements TRT by supporting adrenal pathways. In women, it provides balanced androgen support without the potency of direct testosterone. It is often combined with pregnenolone (upstream precursor), progesterone, and sex hormones as part of full bioidentical HRT.

References

  1. Baulieu et al. - DHEAge study: DHEA replacement in aging men and women (2000)
  2. Intrarosa (prasterone) FDA approval for vulvovaginal atrophy
  3. Arlt et al. - DHEA replacement in women with adrenal insufficiency (1999)
  4. Traish et al. - DHEA: a comprehensive review of clinical implications (2011)

Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.

Launch a Peptide Program With Karpa

Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.

Explore peptide programs